SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update

Ads

You May Also Like

Editas Medicine Announces First Quarter 2018 Results and Update

Expanded Celgene collaboration to drive lead oncology program in solid tumors Strengthened Board of ...

US Department of Defense Research Collaboration Moves Forward

Key Highlights: Three US Defense Health funded research projects on Travelan® successfully completedStudies commissioned ...

TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007

 REGULATED INFORMATIONPRESS RELEASE Transparency notification pursuant to Article 14 of the Law of May ...